Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...

After hours: March 18 at 7:59:54 PM EDT Loading Chart for MRNA ...

A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time. At its peak in 2021, Moderna traded for over $450 per share.

ICIT builds on the promise of circular mRNAs, a new generation of mRNA treatments known for their stability and reduced inflammatory effects compared to traditional linear mRNAs. Unlike linear ...

A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Viruses ...

The study found that the new mRNA vaccine was successful in triggering an immune defense response that helped to reduce TB numbers in infected mice. In addition, the researchers discovered that ...

Forbes contributors publish independent expert analyses and insights.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

A new study has revealed that a mRNA vaccine against tuberculosis has been shown to effectively boost immunity in pre-clinical trials conducted in mice. According to the researchers, the results ...